Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Goodwill (2022 - 2026)

Collegium Pharmaceutical has reported Goodwill over the past 4 years, most recently at $145.9 million for Q4 2025.

  • For Q4 2025, Goodwill fell 10.11% year-over-year to $145.9 million; the TTM value through Dec 2025 reached $145.9 million, down 10.11%, while the annual FY2025 figure was $145.9 million, 10.11% down from the prior year.
  • Goodwill for Q4 2025 was $145.9 million at Collegium Pharmaceutical, roughly flat from $145.9 million in the prior quarter.
  • Over five years, Goodwill peaked at $162.3 million in Q4 2024 and troughed at $130.1 million in Q2 2022.
  • A 4-year average of $139.2 million and a median of $133.9 million in 2023 define the central range for Goodwill.
  • Biggest five-year swings in Goodwill: rose 21.27% in 2024 and later decreased 10.11% in 2025.
  • Year by year, Goodwill stood at $133.7 million in 2022, then grew by 0.12% to $133.9 million in 2023, then increased by 21.27% to $162.3 million in 2024, then dropped by 10.11% to $145.9 million in 2025.
  • Business Quant data shows Goodwill for COLL at $145.9 million in Q4 2025, $145.9 million in Q3 2025, and $147.9 million in Q2 2025.